Peer-influenced content. Sources you trust. No registration required. This is HCN.
Hematology Advisor
Final analysis confirms venetoclax plus modified intensive chemotherapy achieves durable remissions with 17.9-month treatment-free intervals in fit elderly AML patients, particularly those with de novo disease.
Clinical Pharmacology July 22nd 2025
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS